Literature DB >> 8182532

High lipophilicity decreases drug transport across intestinal epithelial cells.

P Wils1, A Warnery, V Phung-Ba, S Legrain, D Scherman.   

Abstract

It is generally admitted in drug research that the passage of molecules across cellular barriers increases with lipophilicity and that the most lipophilic compounds will have the highest intestinal absorption. Using two in vitro models of intestinal epithelium, we presently demonstrate that this concept is not always valid and that highly lipophilic compounds display a low transepithelial permeability. We used epithelial cell lines grown on permeable filters to measure in vitro the transepithelial permeability of various molecules. The octanol/buffer distribution coefficient of the drugs (Do/b) was taken as an index of lipophilicity. When log Do/b values were lower than 3.5, the transepithelial permeability coefficient increased with the lipophilicity. But for log Do/b values ranging from 3.5 to 5.2, the transepithelial permeability coefficient decreased with increasing lipophilicity. Identical results were observed with two differentiated intestinal epithelial cell lines (HT29-18-C1 and Caco-2) and in unstirred or agitated conditions. The results show that an octanol/buffer distribution coefficient value around 3000 corresponds to an optimal transepithelial passage of drugs and that too high a lipophilicity can result in low intestinal epithelial permeability and in low oral absorption.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8182532

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  25 in total

1.  Differentiated intestinal epithelial cell lines as in vitro models for predicting the intestinal absorption of drugs.

Authors:  P Wils; A Warnery; V Phung-Ba; D Scherman
Journal:  Cell Biol Toxicol       Date:  1994-12       Impact factor: 6.691

2.  Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds.

Authors:  M Yazdanian; S L Glynn; J L Wright; A Hawi
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

3.  Transport of the antibacterial agent oxazolidin-2-one and derivatives across intestinal (Caco-2) and renal (MDCK) epithelial cell lines.

Authors:  G Ranaldi; P Seneci; W Guba; K Islam; Y Sambuy
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 4.  Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.

Authors:  Clara Hartmanshenn; Megerle Scherholz; Ioannis P Androulakis
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-09-19       Impact factor: 2.745

Review 5.  Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.

Authors:  H Lennernäs; G Fager
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

6.  Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat.

Authors:  N Hussain; P U Jani; A T Florence
Journal:  Pharm Res       Date:  1997-05       Impact factor: 4.200

7.  Structural determinants of P-glycoprotein-mediated transport of glucocorticoids.

Authors:  Charles R Yates; Cheng Chang; Jeffrey D Kearbey; Kazuto Yasuda; Erin G Schuetz; Duane D Miller; James T Dalton; Peter W Swaan
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

8.  Optimisation of the caco-2 permeability assay using experimental design methodology.

Authors:  Mark Lakeram; David J Lockley; Ruth Pendlington; Ben Forbes
Journal:  Pharm Res       Date:  2008-02-22       Impact factor: 4.200

9.  Formulation-based approach to support early drug discovery and development efforts: a case study with enteric microencapsulation dosage form development for a triarylmethane derivative TRAM-34; a novel potential immunosuppressant.

Authors:  Abeer M Al-Ghananeem; Maggie Abbassi; Srishti Shrestha; Girija Raman; Heike Wulff; Lara Pereira; Aftab Ansari
Journal:  Drug Dev Ind Pharm       Date:  2010-05       Impact factor: 3.225

10.  Preclinical studies of YK-4-272, an inhibitor of class II histone deacetylases by disruption of nucleocytoplasmic shuttling.

Authors:  Hye-Sik Kong; Shuo Tian; Yali Kong; Guanhua Du; Li Zhang; Mira Jung; Anatoly Dritschilo; Milton L Brown
Journal:  Pharm Res       Date:  2012-07-27       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.